Clinical Characteristics of Pediatric Patients with LRBA Deficiency in Mexico

Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2022;42(7):1473–507. https://doi.org/10.1007/s10875-022-01289-3. Lo B, Zhang K, Lu W, et al. Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436–40. https://doi.org/10.1126/science.aaa1663 Kiykim A, Ogulur I, Dursun E, et al. Abatacept as a long-term targeted therapy for LRBA deficiency. J Allergy Clin Immunol Pract Nov-Dec. 2019;7(8):2790-2800.e15. https://doi.org/10.1016/j.jaip.2019.06.011. Tesch VK, Abolhassani H, Shadur B, et al. Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score. J Allergy Clin Immunol. 2020;145(5):1452–63. https://doi.org/10.1016/j.jaci.2019.12.896. Brunner HI, Wong R, Nys M, et al. Paediatric rheumatology international trials organisation (PRINTO) and the pediatric rheumatology collaborative study group (PRCSG). Abatacept: a review of the treatment of polyarticular-course juvenile idiopathic arthritis. Paediatr Drugs. 2020;22(6):653–672. https://doi.org/10.1007/s40272-020-00422-2 Taghizade N, Babayeva R, Kara A, et al. Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency. J Allergy Clin Immunol. 2023;S0091–6749(23):01017–25. https://doi.org/10.1016/j.jaci.2023.08.004.